XENERA™-1: A phase II trial of xentuzumab in combination with everolimus and exemestane in patients with hormone-receptor positive, human epidermal growth factor receptor-2-negative metastatic breast cancer and non-visceral involvement
Peter Schmid, Hope S. Rugo, Javier Cortés, Dennis Chin-Lun Huang, Kate Crossley, Dan Massey, Howard A. Burris
FOR HEALTHCARE PROFESSIONALS ONLY.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue